Search Results - "Munsey, Mark S."

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors by Ricart, Alejandro D., Ashton, Edward A., Cooney, Matthew M., Sarantopoulos, John, Brell, Joanna M., Feldman, Maria A., Ruby, Kale E., Matsuda, Kazuko, Munsey, Mark S., Medina, Gerardo, Zambito, Angela, Tolcher, Anthony W., Remick, Scot C.

“…Purpose MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton…”
Get full text

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors by Traynor, Anne M., Gordon, Michael S., Alberti, Dona, Mendelson, David S., Munsey, Mark S., Wilding, George, Gammans, Richard E., Read, William L.

“…Summary Purpose : To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of MN-209, a novel vascular disrupting…”
Get full text

Synthesis of isoxazolylphosphazene by MUNSEY, M. S, NATALE, N. R

Get full text

Preparation of crown ethers with isoxazolyl-lariats : homologation of isoxazole aldehydes, and a critical comparison of lariat functional moieties for lanthanide extraction by XIONG BING XIA, MUNSEY, M. S, HONGSHAN DU, WAI, C. M, NATALE, N. R

Get full text